{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:22:08Z","timestamp":1754598128527,"version":"3.37.3"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bispecific antibodies (BsAbs) are monoclonal antibodies that simultaneously bind to a specific antigen on tumors and CD3 on T cells, leading to T cell activation and subsequent tumor cell lysis. Several CD20\u00a0\u00d7\u00a0CD3 BsAbs are being developed for B-cell lymphomas. Furthermore, multiple clinical trials to evaluate BsAbs for the treatment of multiple myeloma, with targets including BCMA, GPRC5D and FcRH5, are ongoing. Emerging evidence suggests promising efficacy in heavily pretreated patients with relapsed or refractory lymphoid malignancies, showing an overall response rate of 50\u201360%, with complete response rates of 30\u201340% for relapsed or refractory large B-cell lymphoma and 60\u201370% for relapsed or refractory multiple myeloma. Their toxicity profiles are generally consistent with other T-cell redirecting therapies, including cytokine release syndrome, which may be mitigated with several strategies, such as step-up dosing, pre-mediation with glucocorticoids and a subcutaneous route of administration, and very rare neurotoxicity. Several clinical trials evaluated BsAbs in combination with other agents or in earlier lines of treatment, including in front-line settings. BsAbs have the potential to change the treatment paradigm of lymphoid malignancies in the coming years; however, longer follow-ups are required to assess the durability of responses to these agents. We herein provide an overview of the findings of recent clinical trials on BsAbs, including mechanisms of action, safety profiles, and efficacy, and discuss the role of BsAbs in the treatment of B-cell lymphomas and multiple myeloma.<\/jats:p>","DOI":"10.1093\/jjco\/hyad186","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T05:59:03Z","timestamp":1704520743000},"page":"376-385","source":"Crossref","is-referenced-by-count":2,"title":["Recent advances and future perspectives of T-cell engagers in lymphoid malignancies"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-2030","authenticated-orcid":false,"given":"Yuko","family":"Shirouchi","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"2024040806012116300_ref1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"2024040806012116300_ref2","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2021-148948","article-title":"Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL)","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"key":"2024040806012116300_ref3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024040806012116300_ref4","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"2024040806012116300_ref5","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"2024040806012116300_ref6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"2024040806012116300_ref7","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"2024040806012116300_ref8","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024040806012116300_ref9","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2024040806012116300_ref10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"2024040806012116300_ref11","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2022-158406","article-title":"Odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"2024040806012116300_ref12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024040806012116300_ref13","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2022-157729","article-title":"Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphomas (B-NHLs): updated results from a phase I\/II study","volume":"140","author":"Budde","year":"2022","journal-title":"Blood"},{"key":"2024040806012116300_ref14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with Lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"2024040806012116300_ref15","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"key":"2024040806012116300_ref16","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1200\/JCO.2023.41.16_suppl.7549","article-title":"Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase Ib study","volume":"41","author":"Dickinson","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024040806012116300_ref17","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1200\/JCO.2022.40.16_suppl.7523","article-title":"First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): phase 1\/2 data update","volume":"40","author":"Falchi","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024040806012116300_ref18","doi-asserted-by":"crossref","first-page":"TPS7592","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7592","article-title":"Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2","volume":"41","author":"Sehn","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024040806012116300_ref19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-136295","article-title":"Mosunetuzumab, a novel CD20\/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"key":"2024040806012116300_ref20","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood-2022-157768","article-title":"Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"key":"2024040806012116300_ref21","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"2024040806012116300_ref22","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years","volume":"28","author":"Kristinsson","year":"2014","journal-title":"Leukemia"},{"key":"2024040806012116300_ref23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.16674","article-title":"Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017","volume":"191","author":"Langseth","year":"2020","journal-title":"Br J Haematol"},{"key":"2024040806012116300_ref24","first-page":"501","article-title":"T cell engagement without cytokine storm: a novel BCMA x CD3 antibody killing myeloma cells with minimal cytokine secretion","volume":"130","author":"Buelow","year":"2017","journal-title":"Blood"},{"key":"2024040806012116300_ref25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jha2.69","article-title":"Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed\/refractory multiple myeloma","volume":"1","author":"Foureau","year":"2020","journal-title":"EJHaem"},{"key":"2024040806012116300_ref26","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024040806012116300_ref27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2024040806012116300_ref28","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"2024040806012116300_ref29","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2024040806012116300_ref30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"2024040806012116300_ref31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"2024040806012116300_ref32","doi-asserted-by":"crossref","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep"},{"key":"2024040806012116300_ref33","doi-asserted-by":"crossref","first-page":"10140","DOI":"10.1182\/blood-2022-159969","article-title":"Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed\/refractory multiple myeloma: a phase 1\/2 first-in-human study","volume":"140","author":"Bumma","year":"2022","journal-title":"Blood"},{"key":"2024040806012116300_ref34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2021-148813","article-title":"Phase 1b results for subcutaneous talquetamab plus daratumumab in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Chari","year":"2021","journal-title":"Blood"},{"key":"2024040806012116300_ref35","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024040806012116300_ref36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"2024040806012116300_ref37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"2024040806012116300_ref38","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration Cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/4\/376\/57174394\/hyad186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/4\/376\/57174394\/hyad186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T06:01:39Z","timestamp":1712556099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/4\/376\/7511991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,1,5]]},"published-print":{"date-parts":[[2024,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad186","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,1,5]]}}}